Moderate physical activity may not decrease the risk of cardiovascular disease in persistently overweight and obesity adults

In the worldwide, cardiovascular diseases (CVDs) is the leading cause of mortality with a major contributor to disability, according to the Global Burden of Disease Study 2019 [1, 2]. CVDs, principally ischemic heart disease and stroke, account for 40% of the cause of deaths in the Chinese population [3]. The dramatic increase in obesity and overweight prevalence was caused by changes in dietary and physical activity patterns, especially during the past two decades of rapid economic growth in China [4, 5].

The relationship of obesity and CVDs has been widely discussed over recent years. Most epidemiological evidences supporting a link between obesity and CVDs are based on one time point assessment [6, 7]. In addition, obesity was also significantly associated with higher all-cause mortality [8, 9]. However, despite these adverse effects on increasing the risk of CVDs, numerous studies demonstrated the obesity paradox, where CVDs patients with overweight and obesity seem to have a survival advantage [10‐12]. Previous research has highlighted the need to take into account the time-varying nature of obesity and changes in weight status over the lifespan to understand the true relationship of obesity and disease risk [13]. Although body mass index (BMI) is widely acceptable to evaluate weight status and related disease risk, a simple classification of overweight and obesity by BMI at one point time may not be sufficient to explain long-term weight. Moreover, considering longitudinal changes in obesity and their associations with CVDs and mortality may help direct us toward a more meaningful clinical question, because it provides insight as to whether intervening on the BMI pathway is in fact able to provide a survival benefit.

Physical activity (PA) is closely related to obesity, and any comprehensive study focused on obesity should take PA into account. Several studies have confirmed that PA is related to lower risk of CVDs and longer life expectancy [14, 15]. In addition, studies also showed that participants with overweight or obesity but active PA were not associated with a higher CVDs risk [16, 17]. However, a recent study involving 527,662 participants showed that obesity or overweight was associated an increased risk of CVDs regardless of PA levels, which similar with several cohort studies [18‐20]. Thus, it is necessary to investigate the association between long-term trajectory of joint PA-BMI phenotypes and outcomes.

In the study, we used the group-based trajectory model (GBTM) to identify distinct trajectories of joint phenotypes of obesity and PA and to examine the associations between these long-term variation trajectories and risks of CVDs (including myocardial infarction (MI) and stroke) and all-cause mortality.

Of 101,510 participants were enrolled, 10,646 participants were excluded due to missing information on BMI or PA (n = 5659), history of stroke or MI (n = 3334), CVDs at baseline (n = 715), and BMI of less than 18.5 kg/m² (n = 3290). In addition, we excluded participants with less than 3 times repeatedly measurement of joint BMI-PA phenotypes status due to loss to follow-up including occurring CVDs (n = 2723) or all-cause mortality (n = 1128) during 2006 to 2016, respectively (Fig. 1). Finally, the trajectories of joint BMI-PA phenotypes and their association with future CVDs and all-cause mortality risk were examined among the remaining 88,141 (accounting for 97% of samples) and 89,736 participants (accounting for 98.76% of samples), respectively.

We categorized the study population into six observed discrete trajectories to predict incident CVDs (Fig. 2a): 34.13% of participants who remained within the OWMPA range during 11 follow-up years (referred to as “persistent OW with moderate active physical activity (MPA)” group); 31.35% of the participants who remained within the NWMPA range during 11 follow-up years (referred to as “persistent NW with MPA” group); 13.46% of the participants who remained within the OMPA range during 11 follow-up years (referred to as “persistent obesity with MPA” group); 8.29% of participants who started with NWMPA status and experienced an increase from NW to OW with MPA (referred to as “rising to OW in NW status with MPA” group); 7.87% of the participants who started with OWMPA status and experienced an decrease from OW to NW with MPA (referred to as “decline to NW in OW status with MPA” group); and 4.90% of the participants who started with OMPA status and experienced an decrease from obesity to OW with MPA (referred to as “decline to OW in obesity status with MPA” group). Similarly, we categorized the study population into five observed discrete trajectories to predict all-cause mortality (Fig. 2b): 36.00% of participants who remained within the OWMPA range during 11 follow-up years (referred to as “persistent OW with MPA” group); 31.65% of participants who started with NWAPA status and experienced an increase from NW to OW and a decrease from active physical activity (APA) to MPA (referred to as “rising to OW with MPA in NW status with APA” group); 15.96% of the participants who remained within the OMPA range during 11 follow-up years (referred to as “persistent obesity with MPA” group); 8.75% of the participants who remained within the NWMPA range during 11 follow-up years (referred to as “persistent NW with MPA” group); 7.64% of the participants who started with OWMPA status and experienced an decrease from OW to NW with MPA (referred to as “decline to NW in OW status with MPA” group). The baseline characteristics of participants according trajectory groups are presented in Additional file 1: Table S1, S2. Trajectory groups with obesity were more likely to be had higher proportion of older individuals, history of disease (hypertension, diabetes, and hyperlipidemia), and tea drinker, longer seat time, higher level of salt intake, lower high-density lipoprotein cholesterol (HDL-C), and higher blood pressure, waist circumference (WC), hip circumference (HC), triglycerides (TG), total cholesterol (TC), fasting blood glucose (FBG), CRP, and low-density lipoprotein cholesterol (LDL-C), compared with other trajectory groups.

The unadjusted and adjusted cumulative incidence of CVDs and all-cause mortality according to the trajectory groups (Fig. 3). After adjusting covariates, persistent OW with MPA (HR: 1.31, 95% CI: 1.22–1.41), decline to OW in obesity status with MPA (HR: 1.15, 95% CI: 1.00–1.32), and persistent obesity with MPA (HR: 1.55, 95% CI: 1.41–1.69) were associated with an increased risk of CVDs compared with persistent NW with MPA group (Fig. 4; Table 1). Rising to OW with MPA in NW status with APA (HR: 0.72, 95% CI: 0.65–0.79), persistent OW with MPA (HR: 0.92, 95% CI: 0.87–0.97), and decline to NW in OW status with MPA (HR: 0.73, 95% CI: 0.67–0.80) were associated with a decrease risk of all-cause mortality (Fig. 4; Table 1).

The unadjusted and adjusted cumulative incidence of MI and stroke according to the trajectory groups (Fig. 3). After adjusting covariates, persistent OW with MPA group, decline to OW in obesity status with MPA group, and persistent obesity with MPA group were associated with an increased risk of CVDs compared with persistent NW with MPA group. Different with above results, rising to OW in NW status with MPA group was associated with a decrease risk of MI and persistent obesity with MPA group was not associated with the risk of MI (Fig. 4; Table 1).

In our prospective cohort study of Chinese adults followed biennially from 2006 to 2019, we examined the development of different trajectories of joint phenotypes of BMI and PA during 2006 to 2016, and assessed the associations between these trajectories and risks of CVDs (including MI and stroke) and all-cause mortality. Within the present study, we identified six trajectories and five trajectories using the group-based trajectory analysis for predicting incident CVDs and all-cause mortality, respectively. Compared with persistent NW with MPA group, participants were at 30.8% and 54.5% higher risk of CVDs in the persistent OW with MPA and persistent obesity with MPA trajectory group respectively, while at no increased risk of all-cause mortality in all trajectory groups. These findings were overall robust in sensitivity analyses.

Weight trajectory has been focused on multiple studies, is related to the risk of coronary heart disease [30, 31], type 2 diabetes [32, 33], blood glucose metabolism [34] and cancers [35]. The present study was the first to assess the links between combined BMI and PA phenotype trajectories with the risk of CVDs and all-cause mortality in Chinese adults. Identifying groups of individuals following similar patterns in distinct trajectories might be useful because it may help to identify different pathways by which OW and obesity development and the mechanisms underlying increasing trends. In addition, this allowed us insight in developing early interventions target specific subgroups based on these distinct trajectories [36].

There was a large cohort study described that waist circumference trajectories (including moderate stable, moderate-high stable and high stable group) were associated with risk of CVDs including stroke and MI [37]. A previously systematic review presented that excess BMI with PA was associated with an increased risk of CVDs, which is consistent with our findings [38]. From the present study, the persistent OW with MPA and persistent obesity with MPA trajectories group were associated with an increased risk of CVDs, suggested that persisting OW or obesity could result in CVDs regardless of PA levels. Although PA can have a positive effect on the cardiovascular system [39], moderate exercise intervention may be ineffective in patients with persistent obesity or overweight. A possible reason presented that severe impairment vascular function attributing from persisting obesity or overweight might not be reversed. Similarly, persisting at high levels of long-term BMI trajectories was strongly associated with cardio-metabolic traits [40]. Previous study demonstrated that participants with obesity but metabolic healthy (MH) were associated with an increased risk for MI [24] compared with MH-NW, which suggested an important influence of obesity or overweight on CVDs. A possible mechanism also demonstrated that it is difficult to lose fat when we get fatter, because our body makes more strongly energy compensation that burned during PA [41]. Therefore, it is importance to maintain healthy weight for decreasing CVDs risk.

Moreover, the decreased risk of all-cause mortality were observed in rising to OW with MPA in NW status with APA, persistent OW with MPA and decline to NW in OW status with MPA trajectories group, this may suggest the existence of the “obesity paradox” [42]. It is possibility participants with MPA might be a state of MH in the present study, because PA was associated with levels of cardiorespiratory and metabolic fitness [43]. Previous studies also presented that participants with MH and obesity (MHO) or MH and overweight (MHOW) was not associated with all-cause mortality [44‐46], which suggested MH status might be associated with decrease all-cause mortality. Metabolic phenotypes were associated with body fat distribution patterns including visceral and ectopic fat, which might indirectly result in development of diseases [47]. A possible fat distribution of participants with MHO or MHOW is a high percentage of gluteofemoral and leg fat mass other than accumulation of visceral fat [48]. Additionally, we previously found that MHOW was the healthiest metabolic phenotype [23], which also suggested the importance of association among metabolic factors, lifestyle factors, and diseases.

Our study is strengthened by the use of large prospective cohort study, including approximately 100,000 participants who were followed-up for more than 13 years, allowed us to perform the joint analyses with sufficient statistical power. The prospective design and high follow-up rates minimized the potential for recall bias and loss to follow-up. Besides, we firstly evaluated trajectories of joint phenotypes using the GBTM and conducted a series of sensitivity analyses to show the robustness of the findings. The GBTM allows us to identify multi-unobserved subpopulation, and examine differences in change among unobserved subpopulations [27].

There were several limitations about this present study. Firstly, information on PA level was mainly self-reported, thus measurement bias could not be completely avoidable. However, the self-reported PA questionnaire was validated and demonstrated fairly reliability [26, 49]. Secondly, we excluded participants with less than 3 times measurements of joint phenotypes during 2006 to 2016, due to loss to follow-up including occurring outcomes or other reasons, which might be loss information of partial participants, underestimating the effects of trajectories on outcomes. However, we included 98% of samples in final analysis, and the impact of excluding above participants on the observed association between trajectories and outcomes could be small. Thirdly, we only used BMI to define participants as overweight or obesity. While BMI is widely used in clinical practice, it may be an imperfect measure. And due to the lack of longitudinal measures on indices of fat distribution, we are unable to account for peripheral obesity and abdominal obesity. Fourthly, this study was not a national representative sample, and the racially-homogenous cohort of East Asian ancestry could limit generalizability, the result need to be interpreted cautiously. Fifthly, due to the largest number of participants with MPA, we identified only six and five trajectories of MPA. We cannot estimate the long-term trajectory of obese or overweight patients with high levels of PA and its relationship with CVDs. Finally, the group-based trajectory analysis identifies the unknown population distribution of trajectories, so the trajectory groups should be considered as clusters of individuals following approximately the same trajectory for homogeneity may be theoretically unrealistic within-class [28].

In the large prospective cohort, six long-term trajectories for CVDs and five trajectories for all-cause mortality of joint phenotypes of BMI and PA were identified and were associated with CVDs and all-cause mortality. Participants were at a higher risk of CVDs in the “persistent OW with MPA” and “persistent obesity with MPA” trajectories group. Our results suggested that persisting OW and obesity participants with MPA may not decrease the risk of CVDs in the trajectory group. We additionally observed the decreased risk of all-cause mortality in trajectories group, suggesting the potential existence of “obesity paradox”.